Does osteoporosis therapy invalidate FRAX for fracture prediction?
Does osteoporosis therapy invalidate FRAX for fracture prediction?
复制标题
DOI：
10.1002/jbmr.1582
复制
发表时间：
2012-06-01
影响因子：
6.2
通讯作者：
Kanis, John A.
中科院分区：
文献类型：
--
作者：
Leslie, William D.;Lix, Lisa M.;Kanis, John A.
骨折风险评估系统（FRAX）的十年骨折风险评估越来越多地用于指导治疗决策。骨质疏松症药物治疗可降低骨折风险，但其效果大于骨矿物质密度（BMD）增加所能解释的。这是否使FRAX的裂缝预测失效还不确定。共有35，764名女性（年龄=50岁）和基线BMD测试（1996-2007）追溯计算FRAX概率。使用省级药房数据库来识别骨质疏松症药物使用。妇女被分为未治疗的，目前高依从性用户[药物拥有率（MPR）=0.80，在一年后BMD测试]，目前低依从性用户（MPR
Ten-year fracture risk assessment with the fracture risk assessment system (FRAX) is increasingly used to guide treatment decisions. Osteoporosis pharmacotherapy reduces fracture risk, but the effect is greater than can be explained from the increase in bone mineral density (BMD). Whether this invalidates fracture predictions with FRAX is uncertain. A total of 35,764 women (age =50 years) and baseline BMD testing (1996-2007) had FRAX probabilities retroactively calculated. A provincial pharmacy database was used to identify osteoporosis medication use. Women were categorized as untreated, current high adherence users [medication possession ratio (MPR) =0.80 in the year after BMD testing], current low adherence users (MPR